An insight into JAK-STAT signalling in dermatology

J A Palanivel, A E Macbeth, N C Chetty, N J Levell

Research output: Contribution to journalArticlepeer-review

38 Citations (Scopus)


Many emerging studies have implicated the Janus kinase/signal transducer and activator of transcription (JAK-STAT) cytokine signalling mechanism in disease pathogenesis. This signalling pathway is involved in haematopoiesis and immune development. Mutations in genes regulating JAK-STAT signalling can cause common inflammatory disorders and myeloproliferative disorders. JAK and STAT inhibitors are new management tools for disorders such as myelofibrosis and rheumatoid arthritis. Evidence suggests that the cytokine components of the JAK-STAT pathways play a crucial role in common skin disorders, including psoriasis and atopic dermatitis. We present an overview for the clinical dermatologist of the significance of these signalling pathways in various skin disorders, and introduce the potential application of JAK and STAT inhibition as a new therapeutic tool in dermatology.

Original languageEnglish
Pages (from-to)513-518
Number of pages6
JournalClinical and Experimental Dermatology
Issue number4
Early online date13 May 2014
Publication statusPublished - Jun 2014


  • Humans
  • Janus Kinases
  • Protein Kinase Inhibitors
  • STAT Transcription Factors
  • Signal Transduction
  • Skin Diseases
  • Journal Article
  • Research Support, Non-U.S. Gov't
  • Review

Cite this